Edition:
United Kingdom

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

15.59USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$15.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
234,215
52-wk High
$26.05
52-wk Low
$10.09

Chart for

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 3.18
Market Cap(Mil.): $426.05
Shares Outstanding(Mil.): 32.72
Dividend: --
Yield (%): --

Financials

  GLYC.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -1.34 -- --
ROI: -38.90 1.56 14.38
ROE: -39.26 2.43 16.07

BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

03 May 2018

BRIEF-GlycoMimetics Announces Proposed Public Offering Of Common Stock

* GLYCOMIMETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

19 Mar 2018

BRIEF-Glycomimetics Reports Q4 Loss Per Share $0.27

* GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS

06 Mar 2018

BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine

* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY

08 Feb 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.57 +1.25
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $36.22 +0.06
Merck & Co., Inc. (MRK.N) $61.03 +0.04
Roche Holding Ltd. (ROG.S) CHF215.45 +4.40
Roche Holding Ltd. (RO.S) CHF220.00 +3.20
Bayer AG (BAYGn.DE) €96.96 +0.33
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates